Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ascendis Pharma

Explore full profile

Long-acting prodrug therapies for rare endocrine diseases

Gentofte Municipality, DenmarkFounded 2007Biotech & Life Sciences
Valuation $16B Market cap · Aug/2026
Revenue $1.48B Latest reported FY
EBITDA $424M Latest reported FY

At a glance

Founded
2007
Headquarters
Gentofte Municipality, Denmark
Listing
IPO 2015
Sector
Biotech & Life Sciences
Power Law
Decacorn$10B+ valuation tierThoroughbred$100M+ revenue

Latest news

Press, funding announcements and product moves mentioning Ascendis Pharma.

See all news

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Series B and later6 investors entered at this stage

Employees mapped 1,417 incl. 3 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
17 countries with
team presence
🇩🇰 Denmark49.2%
🇺🇸 United States33.8%
🇩🇪 Germany8.2%
🇫🇷 France1.8%
🇪🇸 Spain1.6%
Top 5 of 17 shown
Web traffic by country
23K monthly visits
across markets
🇺🇸 United States37.4%
🏳️ Korea10.9%
🏳️ Republic of7.4%
🇫🇷 France6.5%
🇬🇧 United Kingdom5.7%
Top 5 markets shown

Patents

Estimated portfolio value
$234M

112 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Ascendis Pharma was the backer or acquirer, 2018–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Ascendis Pharma's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Where Ascendis Pharma deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        Ascendis Pharma's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about Ascendis Pharma on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Ascendis Pharma on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.